+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Intrinsic Pulsatility of Luteinizing Hormone Release from the Human Pituitary in vitro

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          An in vitro perifusion system was used to investigate the spontaneous luteinizing hormone (LH) release from 10 human fetal (21–23 weeks of gestation) and 1 adult female pituitaries. The pattern of LH release from fetal pituitaries (n = 6) exhibited a remarkable pulsatile character with a mean (±SE) pulse interval of 12.7 + 1.7 min. The mean pulse amplitude was 5.2 ± 0.9 mlU with a nadir to peak increment of 69.5 ± 6.4%. The mean LH release rate was 12.3 ± 3.3 mIU/2 min. Blockade of calcium activity with 0.1 mM verapamil and 4 mM EGTA suppressed the frequency (from 1 pulse/12–20 min to 1 pulse/50–100 min) and amplitude (from 5.4–5.7 mlU to 1.4–2.1 mlU) of this spontaneous pulsatile LH release (n = 2). Administration of 8 nMgonadotropin-releasing hormone induced 255 and 954% increases in LH secretion (n = 2). Each quarter of an adult human pituitary also secreted LH in a pulsatile fashion, with a pulse interval of 15.2 ± 5.6 min, a pulse amplitude of 5.4 ± 0.6 mlU, a nadir to peak increment of 67.5 ± 5.2%, and an overall release rate of 14.8 ± 0.9 mIU/2 min. These studies demonstrate that LH release from the isolated human pituitary in vitro is characterized by high-frequency/low-amplitude pulses, independent of hypothalamic stimulation. Accordingly, this spontaneous calcium-mediated pulsatile LH release apparently reflects the activity of an intrinsic intrapituitary pulse-generating mechanism.

          Related collections

          Author and article information

          S. Karger AG
          02 April 2008
          : 45
          : 5
          : 402-406
          Department of Reproductive Medicine, School of Medicine, University of California, San Diego, La Jolla, Calif., USA
          124765 Neuroendocrinology 1987;45:402–406
          © 1987 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper


          Comment on this article